By partnering with other medical companies, the business is able to further hasten the discovery, development and commercialization of their diagnostics for cancer. They have collaborated with Sanofic, Dyax Corp., Adimab LLC, Actavis, Selexis SA., the U.S. Public Health Service and the University of California. Its therapeutic oncology products are in various stages of clinical trials and are used in the treatment of gynecological cancer, breast, lung, pancreatic, lung, ovarian, glioma, gastric and colorectal cancer.
Merrimack Pharmaceuticals uses network biology in the creation of their functional and predictive computational models of biological systems. This science is an interdisciplinary approach to drug discovery and development. Incorporated in 1994, the company continues to hold its main office in Cambridge, Massachusetts.